stockprofessors.com

Volume Buzzer -Elite Pharmaceuticals Inc (OTCBB:ELTP), Dendreon Corporation (NASDAQ:DNDN), Cannabis Science Inc (OTCMKTS:CBIS), GRAND PACARAIMA GOLD (OTCMKTS:BITC)

 
Repost This

New York, NY -- (SBWIRE) -- 01/13/2014 -- Stock Professors is committed to provide its readers with best analytics on hot penny stocks. Our team of stock trading professional's mission is to analyze, track and rate the top penny stocks to buy in the market today. We realize how tough it is for the ordinary investor to make money in today’s volatile stock market. Some, probably like you turn to penny stocks in order to make huge gains on relatively little capital. Today’s hot Stocks to watch are: Elite Pharmaceuticals Inc (OTCBB:ELTP), Dendreon Corporation (NASDAQ:DNDN), Cannabis Science Inc (OTCMKTS:CBIS), GRAND PACARAIMA GOLD (OTCMKTS:BITC)

Elite Pharmaceuticals Inc (OTCBB:ELTP) remained a volume gainer of 7.44 million shares and the average volume of the stock remained 1.54 million shares. The stock opened the session at $0.17 and was recently trading at $0.190 and the stock escalated 18.07 %. The market capitalization of the stock remained 96.20 million. The half-yearly trend of the stock remained positive 163.97 %. Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufactures of oral, controlled-release products, using technology and the development and manufacture of generic pharmaceuticals.

Why Should Investors Buy ELTP After The Recent Gain? Just Go Here and Find Out

In the recent trading session, Dendreon Corporation (NASDAQ:DNDN) exchanged 10.98 million shares and the average volume remained 3.82 million shares. The stock, in the current trading session, was at $3.29, with the gain of 10.04%. Tracking the three months and 6 months trends, the stock was at 23.77% and -26.95%, respectively. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.

What was the Moving Force behind DNDN on Bullish Run? Read This Research Report

Cannabis Science Inc (OTCMKTS:CBIS) enhanced 5.33% and its trading price was $0.123 recently. The volume of the stock was 31.83 million shares and the average volume remained 24.65 million shares. The stock traded amid the day price range of $0.10 - $0.13. The market capitalization of the stock remained 93.34 million. The beta of the stock remained 10.34. Cannabis Science, Inc. is a development-stage company. Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

For How Long CBIS will fight for Profitability? Read This Trend Analysis report

GRAND PACARAIMA GOLD (OTCMKTS:BITC) exchanged 5.57 million shares in the recent trading session, and its average trading remained 406,223 shares. BITC dropped -22.47 % and was trading at $0.0690. The market capitalization of the stock remained 26.89 million. YTD trend of the stock was positive 6600%.

Will BITC Reach the Bottom after Yesterday’s Correction? Find Out Here

About Stock Professors:
We realize how tough it is for the ordinary investor to make money in today’s volatile stock market. That is why we offer penny stocks to watch and FREE stock picks to all our subscribers. We focus on undervalued and undiscovered penny stocks which are poised for not just short term but also long term growth. StockProfessors.com searches the market to bring you the best penny stocks. So, don’t wait any longer and subscribe to our FREE newsletter to get the hot penny stock picks delivered right in your email inbox!

Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances.

The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://www.stockprofessors.com/disclaimer/